ArticleMaterials today. Bio2026
Single-pore silica nanotherapeutic platform with pH-Responsive NO release for osteoporosis repair.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathological triad of perioperative acute kidney injury: renal microcirculatory hypoxia, mitochondrial damage, and immuno-metabolic reprogramming.Frontiers in immunology · 2026Review
- Association of prognostic nutritional index with fecal incontinence and fecal incontinence severity index in individuals with osteoporosis: mediating roles of C-reactive protein and gamma-glutamyl transferase.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic bone disease with progressive deterioration of the bone microarchitecture. A key trigger for Osteoporosis is oxidative stress damage caused by reactive oxygen species (ROS). Nitric oxide (NO) can prevent excessive production of ROS in the bone microenvironment by regulating the abnormal opening of the mitochondrial permeability transition pore (mPTP). NO, as a highly active molecule, also plays an important role in bone regeneration and bone remodeling. However, its short half-life and unstable release severely limit its clinical application. Herein, a pH-responsive NO-releasing nanotherapeutic platform (GSCe NPs) was developed. Single-pore silica nanoparticles (SPMSNs) were synthesized via calcination of nano selenium core, enabling high loading of the NO donor S-nitrosoglutathione (GSNO). GSNO@SPMSN was aminated and coated with Cerium dioxide (CeO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.